LUXOFT
Excelian , Luxoft Financial Services, and Calypso Technology , a leading provider of capital markets software, have announced an agreement which formally recognises Excelian as an official Calypso partner.
This agreement enables Excelian to strategically partner with Calypso to deliver global system integration services around the Calypso platform. It provides a collaborative framework which directly benefits Excelian Calypso clients, as it takes the relationship a step further by means of shared best practices. In addition, consultants in our growing Calypso practice will gain access to Calypso University and will receive the latest training and certifications.
“Excelian has a proven track record of successful Calypso delivery, and this partnership will unlock new synergies between Excelian’s delivery capability and Calypso’s technical innovation. This partnership brings together a market leading Cross-Asset, Front-to-Back Calypso platform and our best practice vendor integration services to deliver value-add benefits to clients,” said Jeremy Ward, Chief Executive Officer of Excelian. “As a result, customers will benefit from accelerated implementations and upgrades, achieving quicker time-to-market, reduced operational risk, and increased efficiency.”
“This is an excellent opportunity for both firms,” commented Pascal Xatart, Calypso’s Chief Executive Officer. “As our global client base expands, Excelian will allow us to scale our business quickly and at a lower cost for both our customers and ourselves. They are an industry leading systems integrator, and Calypso is committed to providing them with the access they need to ensure our clients receive the highest level of service.”
Prakash Anthony, Head of Calypso for Excelian, added, "This is an exciting and important partnership for Excelian. In today's extremely challenging markets, clients are faced with managing a full range of assets, high volumes, complex strategies, and one-stop-processing, all whilst ensuring they comply with increased regulations and control costs. Because of these increasing demands, financial institutions must ensure that they are using the latest (Calypso) technology to meet these expectations. By cementing our relationship with Calypso, our clients will benefit from accelerated implementation times, lower overall costs, and a more rapid return on investment."
About Calypso Technology, Inc.
Calypso Technology, Inc. is a leading provider of cross-asset front-to-back technology solutions for financial markets. It provides customers with a single platform for consolidation, innovation and growth. With 19 years of experience delivering software and services for trading, risk management, processing and accounting, the Calypso solution helps bring simplicity to complex business and technology challenges. Calypso solutions address needs for the capital markets, investment management, clearing, collateral, treasury and liquidity. Clients can benefit from greater efficiency, improved risk management, better allocation of capital, faster regulatory compliance, quicker time to market and reduced Total Cost of Ownership. Calypso Technology offers solutions that improve reliability, adaptability and scalability.
Calypso is used by over 34,000 market professionals in over 60 countries, representing more than 200 financial institutions across Asia, Americas, Europe, Middle East and Africa. Calypso Technology has over 700 staff in 22 global offices, with headquarters in San Francisco, California. “Calypso” is a registered trademark of Calypso Technology Inc. in the United States, the European Union and other jurisdictions. Other parties’ trademarks or service marks are the property of their respective owners and should be treated as such. www.calypso.com
About Luxoft
Luxoft Holding, Inc (NYSE:LXFT), a leading provider of software development services and innovative IT solutions to a global client base, acquired Excelian in February 2015 to advance and expand its value chain by offering financial services clients a full stack of services.
Luxoft’s software development services consist of core and mission critical custom software development and support, product engineering and testing, and technology consulting. Luxoft’s solutions are based on its proprietary products and platforms that directly impact its clients’ business outcomes and efficiently deliver continuous innovation. The Company develops its solutions and delivers its services from 30 dedicated delivery centres worldwide. It has over 11,000 employees across 36 offices in 19 countries in North America, Mexico, Western and Eastern Europe, Asia Pacific, and South Africa. Luxoft is incorporated in Tortola, British Virgin Islands, has its operating headquarters office in Zug, Switzerland and is listed on the New York Stock Exchange. For more information, please visit http://www.luxoft.com .
Forward-Looking Statements
This news release of Luxoft Holding, Inc (“Luxoft”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include information about possible or assumed future results of our business and financial condition, as well as the results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. These statements are subject to, without limitation, the risk factors discussed under the heading “Risk Factors” in Luxoft’s Annual Report on Form 20-F for the year ended March 31, 2015 and other documents filed with or furnished to the Securities and Exchange Commission by Luxoft. Except as required by law, Luxoft undertakes no obligation to publicly update any forward-looking statements for any reason after the date of this news release whether as a result of new information, future events or otherwise.
All trademarks are recognized and are the property of their respective companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160726005484/en/
Contact:
Luxoft Holding, Inc
Alina V. Plaia, +1 212-964-9900 ext. 2404
Vice-President,
Global Communications
IR@luxoft.com
or
Robin
Carley, +1 212-964-9900 ext. 2267
Manager, Public Relations
rcarley@luxoft.com
or
Calypso
Technology
Chris Shayne, +1 415 530 4147
Director, Global
Communications
chris_shayne@calypso.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom